{"id":"https://openalex.org/W1865757265","doi":"https://doi.org/10.1200/jco.1995.13.5.1160","title":"Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.","display_name":"Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.","publication_year":1995,"publication_date":"1995-05-01","ids":{"openalex":"https://openalex.org/W1865757265","doi":"https://doi.org/10.1200/jco.1995.13.5.1160","mag":"1865757265","pmid":"https://pubmed.ncbi.nlm.nih.gov/7537799"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1995.13.5.1160","doi":"https://doi.org/10.1200/jco.1995.13.5.1160","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1995.13.5.1160","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113801937","display_name":"David William Fennelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D Fennelly","raw_affiliation_strings":["Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067734724","display_name":"Jeffrey Gary Schneider","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Schneider","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113786615","display_name":"D. Spriggs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Spriggs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109129259","display_name":"Carmelo Bengala","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Bengala","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067983681","display_name":"Thomas B. Hakes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Hakes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049752917","display_name":"LILIAN M. REICH","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Reich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103697702","display_name":"R.R. Barakat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Barakat","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025145184","display_name":"John Patrick Curtin","orcid":"https://orcid.org/0000-0002-9370-5119","observed_orcids":["https://orcid.org/0000-0002-9370-5119"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Curtin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110863459","display_name":"Malcolm A.S. Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M A Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108628177","display_name":"William J. Hoskins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W Hoskins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":6.4489,"has_fulltext":false,"cited_by_count":43,"citation_normalized_percentile":{"value":0.96636202,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":"5","first_page":"1160","last_page":"1166"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.8899999856948853},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9319999814033508},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.8140000104904175},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.7289999723434448},{"id":"https://openalex.org/keywords/high-dose-chemotherapy","display_name":"high-dose chemotherapy","score":0.824999988079071},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7459999918937683},{"id":"https://openalex.org/keywords/peripheral-blood-progenitor-cells","display_name":"peripheral blood progenitor cells","score":0.7540000081062317},{"id":"https://openalex.org/keywords/filgrastim","display_name":"filgrastim","score":0.6970000267028809},{"id":"https://openalex.org/keywords/leukapheresis","display_name":"leukapheresis","score":0.7839999794960022},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6370000243186951},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7860000133514404},{"id":"https://openalex.org/keywords/platelet-recovery","display_name":"platelet recovery","score":0.5740000009536743},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.777999997138977},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.6710000038146973}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.8718403577804565},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.8537150621414185},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8145068287849426},{"id":"https://openalex.org/C2779171977","wikidata":"https://www.wikidata.org/wiki/Q3151081","display_name":"Filgrastim","level":4,"score":0.556130051612854},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5338491201400757},{"id":"https://openalex.org/C2778670039","wikidata":"https://www.wikidata.org/wiki/Q414004","display_name":"Nitrogen mustard","level":4,"score":0.49135246872901917},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.47533416748046875},{"id":"https://openalex.org/C2778658803","wikidata":"https://www.wikidata.org/wiki/Q1592932","display_name":"Pegfilgrastim","level":5,"score":0.471659779548645},{"id":"https://openalex.org/C2780376820","wikidata":"https://www.wikidata.org/wiki/Q424997","display_name":"Mesna","level":5,"score":0.4666685163974762},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.4625958502292633},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44573238492012024},{"id":"https://openalex.org/C201750760","wikidata":"https://www.wikidata.org/wiki/Q1896218","display_name":"Progenitor cell","level":3,"score":0.44092363119125366},{"id":"https://openalex.org/C2778828106","wikidata":"https://www.wikidata.org/wiki/Q905835","display_name":"Plerixafor","level":5,"score":0.4266383647918701},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3960075080394745},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3881171941757202},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37978264689445496},{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.19251537322998047},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.16684845089912415},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.10097929835319519},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.10065704584121704},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.061907052993774414},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.0},{"id":"https://openalex.org/C129470790","wikidata":"https://www.wikidata.org/wiki/Q415718","display_name":"CXCR4","level":4,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000230","descriptor_name":"Adenocarcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007958","descriptor_name":"Leukocyte Count","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013234","descriptor_name":"Stem Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D015703","descriptor_name":"Antigens, CD","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016190","descriptor_name":"Carboplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018952","descriptor_name":"Antigens, CD34","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1995.13.5.1160","doi":"https://doi.org/10.1200/jco.1995.13.5.1160","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1995.13.5.1160","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:7537799","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7537799","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G280621961","display_name":null,"funder_award_id":"CA 52477-04","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6719681250","display_name":"Epithelial Ovarian Cancer Program Project","funder_award_id":"P01CA052477","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1490988862","https://openalex.org/W1857437878","https://openalex.org/W2063953472","https://openalex.org/W2428733533","https://openalex.org/W2460900515"],"related_works":["https://openalex.org/W2401870037","https://openalex.org/W2411225671","https://openalex.org/W2031972383","https://openalex.org/W2418180823","https://openalex.org/W1990344014","https://openalex.org/W2400802577","https://openalex.org/W2331837574","https://openalex.org/W2313633546","https://openalex.org/W1569520020","https://openalex.org/W2261556684"],"abstract_inverted_index":{"PURPOSE:":[0],"We":[1],"commenced":[2],"a":[3],"phase":[4],"I":[5,54],"study":[6],"of":[7,31,42,45,66,83,111,115,144,170,174,190,208,245,250,263,275],"escalating":[8],"dose":[9],"Taxol":[10,51,252],"(paclitaxel;":[11],"Bristol-Myers":[12],"Squibb":[13],"Co,":[14],"Wallingford,":[15],"CT)":[16],"in":[17,64,266],"addition":[18,249],"to":[19,21,55,76,136,165,172,187,202,253],"cyclophosphamide,":[20],"assess":[22],"its":[23],"impact":[24],"on":[25],"both":[26],"antitumor":[27],"efficacy":[28],"and":[29,60,74,87,90,119,189,233,291],"mobilization":[30],"peripheral-blood":[32],"progenitor":[33],"cells":[34],"(PBP).":[35],"PATIENTS":[36],"AND":[37],"METHODS:":[38],"Induction":[39],"therapy":[40],"consisted":[41],"two":[43,234],"cycles":[44,110,114,143],"cyclophosphamide":[46,88,255],"3.0":[47],"g/m2":[48],"plus":[49,68],"escalating-dose":[50,251],"(dose":[52],"levels":[53],"IV,":[56],"150,":[57],"200,":[58],"250,":[59],"300":[61],"mg/m2,":[62],"respectively)":[63],"cohorts":[65],"three,":[67],"filgrastim":[69],"granulocyte":[70],"colony-stimulating":[71],"factor":[72],"[G-CSF])":[73],"leukaphereses":[75],"harvest":[77],"PBP,":[78],"followed":[79],"by":[80],"four":[81],"courses":[82,130,152],"rapidly":[84],"cycled":[85],"carboplatin":[86],"(1,000":[89],"1,500":[91],"mg/m2":[92],"per":[93],"course,":[94],"respectively),":[95],"for":[96,128,150,215,240],"which":[97],"hematopoietic":[98],"rescue":[99,154],"was":[100,131,155,160,183,205],"achieved":[101,156],"with":[102,121,157,221,228,236,280],"PBP.":[103,122],"RESULTS:":[104],"Sixteen":[105],"patients":[106,139,213,220,227,235],"completed":[107,140],"all":[108,141],"planned":[109,142],"Taxol/cyclophosphamide.":[112],"Fifty-four":[113],"carboplatin/cyclophosphamide":[116,151],"were":[117,218],"given":[118],"rescued":[120],"The":[123,146,167,248,261,285],"median":[124,147,168],"interval":[125,149],"between":[126],"treatments":[127],"Taxol/cyclophosphamide":[129],"14":[132,164],"days":[133,162,171],"(range,":[134,163,185,200],"13":[135,212],"21).":[137],"Twelve":[138],"carboplatin/cyclophosphamide.":[145,277],"inter-treatment":[148],"when":[153],"Taxol/cyclophosphamide-primed":[158],"PBP":[159,259,264],"17":[161],"25).":[166],"number":[169],"recovery":[173],"an":[175,241],"absolute":[176],"neutrophil":[177],"count":[178,193],"(ANC)":[179],"greater":[180,194],"than":[181,195],"0.5":[182],"8":[184,201],"5":[186],"12),":[188],"self-sustaining":[191],"platelet":[192],"20":[196],"x":[197],"10(9)/L,":[198],"11":[199],"15).":[203],"There":[204],"one":[206],"episode":[207],"fatal":[209],"sepsis.":[210],"Of":[211],"assessable":[214],"response,":[216],"there":[217],"five":[219],"pathologic":[222,237],"complete":[223],"responses":[224],"(38.5%),":[225],"six":[226],"microscopic":[229],"residual":[230],"disease":[231],"(46%),":[232],"partial":[238],"responses,":[239],"overall":[242],"response":[243,286],"rate":[244],"100%.":[246],"CONCLUSION:":[247],"high-dose":[254,276],"does":[256],"not":[257],"compromise":[258],"mobilization.":[260],"use":[262],"mobilized":[265],"this":[267,281],"fashion":[268],"provides":[269],"reliable":[270],"engraftment":[271],"after":[272],"sequential":[273],"administration":[274],"Toxicities":[278],"produced":[279],"approach":[282],"are":[283,289],"manageable.":[284],"rates":[287],"demonstrated":[288],"promising":[290],"warrant":[292],"further":[293],"evaluation.":[294]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}